VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
KURAKura Oncology, Inc.
$10.36$920M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksKURAEarnings History

KURA logoKura Oncology, Inc. (KURA) Earnings History

Net Loss

18 years of earnings data (2008–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$295M
● Net Loss
TTM EPS (Diluted)
$-3.32
Per share, diluted
YoY EPS Growth
-57.4%
Declining
Net Margin
-412.9%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-449.9%
Gross Margin99.9%
Return on Equity-94.8%
Return on Assets-37.2%
Record Annual Net Income-$19,996FY2009
Record Quarterly EPS$-0.00Q4 2011
Consecutive Profitable Years0years
Q1 2026
Net Income-$73M
EPS (Diluted)$-0.83
YoY Growth-57.4%Declining
QoQ Growth+9.5%Solid

Loading earnings history...

Kura Oncology, Inc. (KURA) Earnings Overview

As of June 22, 2026, Kura Oncology, Inc. (KURA) reported trailing twelve-month net income of -$295M, reflecting -57.4% year-over-year growth. The company earned $-3.32 per diluted share over the past four quarters, with a net profit margin of -412.9%.

Looking at the long-term picture, KURA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$19,996 in fiscal 2009.

Kura Oncology, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including MGNX (-$70M net income, -49.9% margin), TPVG (-$12M net income, 50.6% margin), AGIO (-$423M net income, -764.0% margin), KURA has room to improve margins relative to the peer group. Compare KURA vs MGNX →

KURA Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
KURA logoKURACurrent
-$295M$-3.32-412.9%-94.8%-57.4%—
MGNX logoMGNX
-$70M$-1.11-49.9%-86.9%-10.3%
TPVG logoTPVG
-$12M$-0.1050.6%14.1%+48.8%
AGIO logoAGIO
-$423M$-7.19-764.0%-30.2%-161.2%
IMVT logoIMVT
-$506M$-2.48--64.8%-1.5%
RVMD logoRVMD
-$1.4B$-6.92--58.1%-66.2%
Best in group
Lowest in group

KURA Historical Earnings Data (2008–2025)

18 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$279M-60.2%-$304M$-3.18-412.9%-449.9%
2024-$174M-14.0%-$193M$-2.02-322.9%-358.5%
2023-$153M-12.4%-$166M$-2.08--
2022-$136M-4.1%-$140M$-2.03--
2021-$130M-45.6%-$131M$-1.97--
2020-$90M-41.9%-$92M$-1.69--
2019-$63M-4.5%-$67M$-1.51--
2018-$60M-70.6%-$63M$-1.72--
2017-$35M-28.6%-$36M$-1.52--
2016-$28M-21.8%-$28M$-1.47--
2015-$23M-105.4%-$24M$-2.28--
2014-$11M-40218.5%-$12M$-2.69--
2013$-27,315-1.0%$-22,341$-0.01--
2012$-27,040-20.7%$-23,440$-0.01--
2011$-22,395+0.0%$-20,509$-0.00--
2010$-22,395-12.0%$-41,018$-0.00--
2009$-19,996+40.5%$-38,316$-0.00--
2008$-33,623-$-33,623$-0.01--

Download Data

Export KURA earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

18+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

KURA — Frequently Asked Questions

Quick answers to the most common questions about buying KURA stock.

What is KURA earnings per share (EPS)?

KURA trailing twelve-month (TTM) diluted EPS is $-3.32, reflecting -57.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2008 to 2025 is available in the table on this page.

What is Kura Oncology, Inc.'s net income?

Kura Oncology, Inc. (KURA) trailing twelve-month net income is $-295M as of 2025. Earnings declined -57.4% year-over-year.

Is KURA profitable?

KURA is not currently profitable on a TTM basis, reporting a net loss of $-295M. Net margin is -412.9%. Investors should monitor for a return to profitability.

What is KURA's earnings growth rate?

KURA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2008 to 2025.

What are KURA's profit margins?

Kura Oncology, Inc. net profit margin is -412.9%, operating margin is -449.9%, and gross margin is +99.9%. Below-average margins reflect competitive or cost pressures. Return on Equity is -94.8%.

Is KURA growing earnings?

KURA earnings are declining — EPS fell -57.4% year-over-year. TTM net income dropped to $-295M. This contrasts with the 5-year CAGR of N/A.

What was KURA's best earnings year?

Kura Oncology, Inc.'s highest annual net income on record is $-19996.00, achieved in fiscal year 2009. Earnings history on this page spans 2008 to 2025 and includes all annual and quarterly figures.

What were KURA's earnings last quarter?

KURA's most recent reported quarter was Q1 2026. Net income was $-73M with diluted EPS of $-0.83. For a full breakdown of all quarters, see the quarterly earnings table on this page.

KURA Earnings Over Time (2008–2025)

Net income & EPS — annual and quarterly view